WASHINGTON— The cost of prescription skin treatments has skyrocketed since 2009, as the burden of escalating drug prices increasingly weighs on family budgets. Of the 19 brand-name drugs analyzed in the study published Wednesday, price hikes have been most extreme for two drugs made by Valeant Pharmaceuticals International Inc., which has been subpoenaed...» Read More
Drug maker Novartis reported a better-than-expected rise in first-quarter profit, thanks to strong vaccine sales, while quarterly sales at Nestle also beat expectations.
Eli Lilly Monday posted lower-than-expected quarterly earnings, as disappointing sales of its Byetta diabetes drug overshadowed growing demand for its other medicines, sending shares 3.4 percent lower.
Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
Roche Holding missed forecasts with a meagre 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs.
The world's biggest drug company kicked off pureplay pharma earnings season this morning with disappointing results that look to be dragging down the whole sector. PFE missed Wall Street expectations on revenue and profits.
European shares fell on Thursday, led lower by Nokia after the world's biggest maker of mobile phones failed to impress investors with its outlook, dragging down other technology and telecom stocks.
Pfizer on Thursday reported a worse-than-expected decline in first-quarter earnings after declining sales of cholesterol fighter Lipitor and medicines now facing generic competition, sending shares down almost 4 percent.
Ahead of earnings Thursday, Pfizer announced plans to license a brain cancer drug from Avant Immunotherapeutics. Will Pfizer continue to buy its way to a promising drug pipeline?
The world's biggest pharma company is stepping up to the plate again. After the closing bell today PFE announced it's doing a deal worth up to $440 million over time with a baby biotech called Avant Immunotherapeutics.
After navigating what has to be one of the most frustrating paths to Food and Drug Administration approval of a new drug, the small biopharma company Pozen and its big pharma partner GlaxoSmithKline have finally emerged victorious.
Abbott Laboratories said Wednesday first-quarter earnings increased 34 percent on higher sales of its prescription drugs and medical devices and favorable foreign exchange factors.
Johnson & Johnson posted better-than-expected first-quarter earnings on Tuesday, sending its shares higher, as aggressive cost cutting helped offset plunging sales of anemia drugs hit by safety concerns and medicines facing generic competition.
Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?
A new report in the Journal of the American Medical Association is highly critical of drugmaker Merck and its handling of the painkiller Vioxx.
It's not Carl Icahn. Earlier this month I blogged about a mysterious institutional investor taking a big stake in the ever-popular biotech Dendreon. DNDN's CFO was quoted as saying the secret admirer was familiar with biotech leading some to speculate it might be the billionaire activist investor who has taken stakes in Biogen-Idec, MedImmune and ImClone, just to name a few.
Forest Laboratories on Tuesday posted a better-than-expected profit, but shares fell 7.5 percent as the mid-sized drugmaker projected only slightly higher full-year earnings due to expenses to improve its product line.
AstraZeneca has settled U.S. patent litigation against India's Ranbaxy Laboratories over its top-selling drug, ulcer pill Nexium, securing future sales and sending its shares soaring.
Can we please get some upside earnings reports this quarter? No financial exposure here. Instead, this Dow Industrial has plenty of overseas business to be helped by the weaker dollar and guardedly optimistic expectations for key business segments.
On Friday I did a sidebar story on what might be ailing General Electric's healthcare business. (Disclosure: CNBC is owned by NBC Universal, which is a unit of GE). It was responsible for a penny of the earnings miss. On "Squawk Box" that morning CEO Jeff Immelt said the longer-than-expected closure of a manufacturing plant was partially to blame.